Sanofi’s protein-based vaccine Nuvaxovid has demonstrated superior tolerability compared to Moderna’s next-generation messenger RNA vaccine, mNexspike, in a recent head-to-head trial. This finding is significant as it highlights the ongoing competition between traditional protein-based vaccines and newer mRNA technologies in the COVID-19 vaccine landscape.
The context of this trial is critical, given the increasing scrutiny on vaccine safety and tolerability, especially as booster campaigns continue globally. With public health authorities emphasizing the importance of vaccine acceptance, data showcasing lower adverse effects could influence healthcare providers’ recommendations and patient choices.
The implications of these results may extend beyond immediate market dynamics. If Nuvaxovid’s tolerability is consistently favored, it could reshape strategic decisions for stakeholders in regulatory, QA/QC, and sourcing sectors, potentially impacting future vaccine development and approval pathways.
Use the database as your supply chain compass →
